{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:22:38Z","timestamp":1783178558300,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ctro.2025.100955","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:33:24Z","timestamp":1744090404000},"page":"100955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Post-treatment changes in bowel and urinary function in prostate cancer patients treated with moderate or ultra-hypofractionation: A prospective cohort study"],"prefix":"10.1016","volume":"53","author":[{"given":"W.D.","family":"Heemsbergen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-5842","authenticated-orcid":false,"given":"F.","family":"Sinzabakira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Franckena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.M.C.","family":"Christianen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7912-3171","authenticated-orcid":false,"given":"F.E.","family":"Froklage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Westerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Incrocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2025.100955_b0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2022.06.014","article-title":"Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFIT","volume":"173","author":"Zhou","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100955_b0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2025.100955_b0015","doi-asserted-by":"crossref","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;8:1047-60. https:\/\/doi.org\/ 10.1016\/S1470-2045(16)30102-4.","DOI":"10.1016\/S1470-2045(16)30102-4"},{"key":"10.1016\/j.ctro.2025.100955_b0020","doi-asserted-by":"crossref","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019;394:385-95. https:\/\/doi.org\/ 10.1016\/S0140-6736(19)31131-6.","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"10.1016\/j.ctro.2025.100955_b0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2025.100955_b0030","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s11136-014-0678-8","article-title":"EMPRO Group Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments","volume":"23","author":"Schmidt","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ctro.2025.100955_b0035","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2014.08.074","article-title":"Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE Registry","volume":"68","author":"Punnen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2025.100955_b0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41416-020-0978-4","article-title":"The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer","volume":"123","author":"Noble","year":"2020","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctro.2025.100955_b0045","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2025.100955_b0050","doi-asserted-by":"crossref","unstructured":"Staffurth JN, Haviland JS, Wilkins A, Syndikus I, Khoo V, Bloomfield D, et al ; CHHiP Trial Management Group. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK\/06\/016). Eur Urol Oncol. 2021;4(6):980-992. doi: 10.1016\/j.euo. 2021.07.005.","DOI":"10.1016\/j.euo.2021.07.005"},{"key":"10.1016\/j.ctro.2025.100955_b0055","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-Reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2025.100955_b0060","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2025.100955_b0065","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2025.100955_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-Reported outcomes Through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation With or Without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2025.100955_b0075","article-title":"Acute toxicity patterns and their management after moderate and ultra- hypofractionated radiotherapy for prostate cancer: A prospective cohort study","volume":"48","author":"Sinzabakira","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100955_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","article-title":"A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer","volume":"78","author":"Arcangeli","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.100955_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT; PROSTQA Consortium","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2025.100955_b0090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/cancers14030517","article-title":"Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer","volume":"14","author":"Nakajima","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2025.100955_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","article-title":"Overview, Update, and Lessons Learned from the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol","volume":"22","author":"Stolk","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.ctro.2025.100955_b0100","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Prostate Testing for Cancer and Treatment (ProtecT) Study Group. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ctro.2025.100955_b0105","first-page":"G301","article-title":"to pee or not to pee? Grundy L, Brierley SM","volume":"314","author":"Cross-organ sensitization between the colon and bladder","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ctro.2025.100955_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1748-717X-5-27","article-title":"Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study","volume":"5","author":"Pinkawa","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100955_b0115","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.ijrobp.2014.08.347","article-title":"Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy","volume":"90","author":"Fiorino","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.100955_b0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/luts.12142","article-title":"Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer","volume":"10","author":"Washino","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ctro.2025.100955_b0125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.01.016","article-title":"CHHiP Investigators. The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial","volume":"100","author":"Wilson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082500045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082500045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T20:17:08Z","timestamp":1752783428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082500045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"alternative-id":["S240563082500045X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2025.100955","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-treatment changes in bowel and urinary function in prostate cancer patients treated with moderate or ultra-hypofractionation: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2025.100955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100955"}}